Compare RBCAA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | AGIO |
|---|---|---|
| Founded | 1974 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 1998 | 2013 |
| Metric | RBCAA | AGIO |
|---|---|---|
| Price | $91.21 | $36.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.00 |
| AVG Volume (30 Days) | 74.8K | ★ 1.0M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $417,495,000.00 | $43,011,000.00 |
| Revenue This Year | N/A | $229.47 |
| Revenue Next Year | $3.20 | $94.99 |
| P/E Ratio | $119.76 | ★ N/A |
| Revenue Growth | ★ 8.50 | N/A |
| 52 Week Low | $63.97 | $22.24 |
| 52 Week High | $102.22 | $46.00 |
| Indicator | RBCAA | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 66.86 |
| Support Level | $88.88 | $32.17 |
| Resistance Level | $93.78 | $44.09 |
| Average True Range (ATR) | 2.00 | 1.43 |
| MACD | 0.07 | 0.73 |
| Stochastic Oscillator | 47.75 | 91.70 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.